AMBIA
BLRX

Allen Mooney & Barnes Investment Advisors’s BioLineRX BLRX Stock Holding History

Allen Mooney & Barnes Investment Advisors’s Portfolio BLRX Stock Details BLRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-375
Closed -$23.6K – 162
2023
Q4 		$23.6K Sell
375
-250
-40% -$15.5K ﹤0.01% 154
2023
Q3 		$45.5K Buy
+625
New +$42K 0.01% 149

Other funds holding BLRX

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
VFA
Values First Advisors Gray, Tennessee $219M AUM 33.32% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
AWS
Atria Wealth Solutions New York $4.42B AUM 16.4% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $424B AUM 22.94% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RG
Rathbones Group Liverpool, United Kingdom $27.1B AUM 20.2% 1-Year Est. Return
GWM
Geneos Wealth Management Englewood, Colorado $4.31B AUM 18.36% 1-Year Est. Return
BRWA
B. Riley Wealth Advisors Boca Raton, Florida $1.87B AUM 37.01% 1-Year Est. Return

Allen Mooney & Barnes Investment Advisors's BLRX Position: Q1 2024 in Review

Allen Mooney & Barnes Investment Advisors sold out of BioLineRX (BLRX) in Q1 2024, closing a stake of 375 shares — an estimated $23.6K sold.

Allen Mooney & Barnes Investment Advisors first reported a position in BLRX in Q3 2023 and held it in 2 quarters. The position peaked at $45.5K in Q3 2023. 29 funds tracked by Wall St. Rank hold BLRX as of Q1 2024.

  • Allen Mooney & Barnes Investment Advisors reported no remaining BioLineRX position as of Q1 2024 after selling out during the quarter.
  • Allen Mooney & Barnes Investment Advisors sold 375 BioLineRX shares in Q1 2024, an estimated $23.6K.
  • Allen Mooney & Barnes Investment Advisors first reported a position in BioLineRX in Q3 2023 and held it in 2 quarters.
  • Allen Mooney & Barnes Investment Advisors's BioLineRX position peaked at $45.5K in Q3 2023.
  • 29 funds tracked by Wall St. Rank held BioLineRX as of Q1 2024.

Based on Allen Mooney & Barnes Investment Advisors's 13F filing for Q1 2024, filed 12 Apr 2024.